Oxford Biomedica (LON:OXB) Releases Earnings Results

Oxford Biomedica (LON:OXB) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%.

Oxford Biomedica Stock Performance

Shares of Oxford Biomedica stock traded down GBX 10 during trading hours on Wednesday, reaching GBX 483. The company had a trading volume of 650,515 shares, compared to its average volume of 1,106,726. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. The firm has a market cap of £584.66 million, a PE ratio of -17.94 and a beta of 1.09. Oxford Biomedica has a one year low of GBX 420 and a one year high of GBX 952. The business has a fifty day simple moving average of GBX 515.68 and a 200 day simple moving average of GBX 577.12.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on OXB. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 595 price target on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 900 price target on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of GBX 580.85.

More Oxford Biomedica News

Here are the key news stories impacting Oxford Biomedica this week:

• Positive Sentiment: Oxford Biomedica reported first-half revenue of £80.2 million, representing approximately 9% growth, while retaining its full-year sales guidance. Record commercial wins and an improving client pipeline are improving revenue visibility. Oxford Biomedica delivers solid H1 growth, record commercial wins
• Positive Sentiment: The company added 17 new clients, supporting expectations for continued expansion in its cell and gene therapy manufacturing business. The improved order pipeline could make future revenue more predictable. OXB wins 17 new clients as its expansion gathers pace
• Positive Sentiment: Oxford Biomedica is advancing a global quality transformation using Veeva Quality Cloud. The initiative may improve operational consistency and compliance as the company scales internationally. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
• Neutral Sentiment: Management maintained its outlook, with analysts highlighting the client pipeline as a source of improving revenue visibility. However, the guidance does not yet indicate a clear near-term path to profitability. OXB outlook maintained as client pipeline improves revenue visibility
• Negative Sentiment: Quarterly EPS was a loss of 30.39 pence, while the company reported a negative 17.85% net margin and negative 48.56% return on equity. The half-year loss widened, offsetting the revenue growth and new-client wins. Oxford Biomedica reiterates sales outlook but half-year loss widens

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.